Literature DB >> 25043618

Fcγ receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid.

Franziska S Schulze1, Tina Beckmann1, Falk Nimmerjahn2, Akira Ishiko3, Mattias Collin4, Jörg Köhl5, Stephanie Goletz1, Detlef Zillikens1, Ralf Ludwig1, Enno Schmidt6.   

Abstract

Bullous pemphigoid (BP) and epidermolysis bullosa acquisita are subepidermal autoimmune blistering diseases mediated by autoantibodies against type XVII collagen (Col17) and Col7, respectively. For blister formation, Fc-mediated events, such as infiltration of inflammatory cells in the skin, complement activation, and release of proteases at the dermal-epidermal junction, are essential. Although in the neonatal passive transfer mouse model of BP, tissue destruction is mediated by Fcγ receptors (FcγRs) I and III, the passive transfer model of epidermolysis bullosa acquisita completely depends on FcγRIV. To clarify this discrepancy, we developed a novel experimental model for BP using adult mice. Lesion formation was Fc mediated because γ-chain-deficient mice and mice treated with anti-Col17 IgG, depleted from its sugar moiety at the Fc portion, were resistant to disease induction. By the use of various FcγR-deficient mouse strains, tissue destruction was shown to be mediated by FcγRIV, FcγRIII, and FcγRIIB, whereas FcγRI was not essential. Furthermore, anti-inflammatory mediators in already clinically diseased mice can be explored in the novel BP model, because the pharmacological inhibition of FcγRIV and depletion of granulocytes abolished skin blisters. Herein, we extended our knowledge about the importance of FcγRs in experimental BP and established a novel BP mouse model suitable to study disease development over a longer time period and explore novel treatment strategies in a quasi-therapeutic setting.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25043618     DOI: 10.1016/j.ajpath.2014.05.007

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

Review 1.  [Immunoadsorption in dermatology].

Authors:  Franziska Hübner; Michael Kasperkiewicz; Detlef Zillikens; Enno Schmidt
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

Review 2.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

3.  Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.

Authors:  Misa Hirose; Anika Kasprick; Foteini Beltsiou; Katharina Dieckhoff Schulze; Franziska Sophine Schulze; Unni Kjsrl Samavedam; Jennifer E Hundt; Hendri H Pas; Marcel F Jonkman; Enno Schmidt; Kathrin Kalies; Detlef Zillikens; Ralf J Ludwig; Katja Bieber
Journal:  Mol Med       Date:  2016-12-20       Impact factor: 6.354

4.  Mast cell-deficient mice Mcpt5Cre/Dicer fl/fl redefine the role of mast cells in experimental bullous pemphigoid.

Authors:  S Nsiah-Dosu; C Scholz; Z Orinska; C D Sadik; R J Ludwig; E Schmidt; D Zillikens; K Hartmann
Journal:  Skin Health Dis       Date:  2021-12-21

5.  Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases.

Authors:  Katja Bieber; Shijie Sun; Mareike Witte; Anika Kasprick; Foteini Beltsiou; Martina Behnen; Tamás Laskay; Franziska S Schulze; Elena Pipi; Niklas Reichhelm; René Pagel; Detlef Zillikens; Enno Schmidt; Tim Sparwasser; Kathrin Kalies; Ralf J Ludwig
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

Review 6.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

7.  Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2.

Authors:  Christian M Karsten; Tina Beckmann; Maike M Holtsche; Jenny Tillmann; Sabrina Tofern; Franziska S Schulze; Eva Nina Heppe; Ralf J Ludwig; Detlef Zillikens; Inke R König; Jörg Köhl; Enno Schmidt
Journal:  Front Immunol       Date:  2018-03-15       Impact factor: 7.561

8.  Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody.

Authors:  Ariane Clapé; Céline Muller; Grégory Gatouillat; Sébastien Le Jan; Coralie Barbe; Bach-Nga Pham; Frank Antonicelli; Philippe Bernard
Journal:  Front Immunol       Date:  2018-03-13       Impact factor: 7.561

9.  The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita.

Authors:  Tamás Németh; Oana Virtic; Cassian Sitaru; Attila Mócsai
Journal:  J Invest Dermatol       Date:  2017-05-30       Impact factor: 8.551

Review 10.  The Role of Mast Cells in Autoimmune Bullous Dermatoses.

Authors:  Xinhua Yu; Anika Kasprick; Karin Hartmann; Frank Petersen
Journal:  Front Immunol       Date:  2018-02-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.